Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study.
COVID-19
SARS-CoV-2
Strongyloides
hyperinfection syndrome
ivermectin
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
10 05 2023
10 05 2023
Historique:
received:
25
04
2023
revised:
04
05
2023
accepted:
08
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
There is negligible evidence on the efficacy of ivermectin for treating COVID-19 pneumonia. This study aimed to assess the efficacy of ivermectin for pre-emptively treating This single-center, observational, retrospective study included patients admitted with COVID-19 pneumonia at Hospital Vega Baja from 23 February 2020 to 14 March 2021. Because strongyloidiasis is endemic to our area, medical criteria support empiric administration of a single, 200 μg/kg dose of ivermectin to prevent Of 1167 patients in the cohort, 96 received ivermectin. After propensity score matching, we included 192 patients. The composite outcome of in-hospital mortality or need for respiratory support occurred in 41.7% of the control group (40/96) and 34.4% (33/96) of the ivermectin group. Ivermectin was not associated with the outcome of interest (adjusted odds ratio [aOR] 0.77, 95% confidence interval [CI] 0.35, 1.69; In hospitalized patients with COVID-19 pneumonia, ivermectin at a single dose for pre-emptively treating
Identifiants
pubmed: 37243224
pii: v15051138
doi: 10.3390/v15051138
pmc: PMC10222278
pii:
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA Intern Med. 2022 Apr 1;182(4):426-435
pubmed: 35179551
N Engl J Med. 2021 Dec 2;385(23):2197-2198
pubmed: 34670041
Chest. 2021 Jan;159(1):85-92
pubmed: 33065103
BMC Infect Dis. 2021 Jul 02;21(1):635
pubmed: 34215210
Pathogens. 2020 Jul 23;9(8):
pubmed: 32717912
J Med Virol. 2021 Oct;93(10):5833-5838
pubmed: 34076901
JAMA. 2022 Oct 25;328(16):1595-1603
pubmed: 36269852
BMJ Glob Health. 2020 May;5(5):
pubmed: 32461226
JAMA. 2021 Apr 13;325(14):1426-1435
pubmed: 33662102
Cochrane Database Syst Rev. 2022 Jun 21;6:CD015017
pubmed: 35726131
Thorax. 2021 Sep;76(9):920-929
pubmed: 33632764
Am J Ther. 2021 Jun 21;28(4):e434-e460
pubmed: 34145166
Cochrane Database Syst Rev. 2021 Jul 28;7:CD015017
pubmed: 34318930
J Immigr Minor Health. 2022 Dec;24(6):1431-1434
pubmed: 35939223
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Chest. 2021 May;159(5):2111-2112
pubmed: 33965138
JAMA. 2020 Aug 18;324(7):623-624
pubmed: 32761166
In Vivo. 2020 Sep-Oct;34(5):3023-3026
pubmed: 32871846
Int J Infect Dis. 2021 Feb;103:214-216
pubmed: 33278625
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Int J Antimicrob Agents. 2022 Feb;59(2):106516
pubmed: 34999239
J Int Med Res. 2021 May;49(5):3000605211013550
pubmed: 33983065
JAMA Netw Open. 2022 Mar 1;5(3):e223079
pubmed: 35311963
Am J Trop Med Hyg. 2020 Oct;103(4):1364-1366
pubmed: 32828137
JACC Case Rep. 2021 Jun 16;3(6):954-959
pubmed: 34317664
Pathog Glob Health. 2021 Jun;115(4):235-242
pubmed: 33682640